• Propanc Biopharma plans to start a Phase 1b first-in-human study of PRP in February 2027 in Australia.
• No clinical results have been presented; initial safety and early activity readouts are expected in the future from this trial.
• The open-label study aims to assess safety, tolerability, drug behavior in the body, immune response, and early signs of antitumor effect.
• Up to 50 patients with advanced solid tumors will be enrolled, with an initial dose-escalation stage followed by expansion cohorts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090830PRIMZONEFULLFEED9823608) on September 09, 2026, and is solely responsible for the information contained therein.